Artur Pałasz1, Magdalena Bandyszewska2, Ewa Rojczyk3, Ryszard Wiaderkiewicz3. 1. Department of Histology, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland. Electronic address: apalasz@sum.edu.pl. 2. Department of Biochemistry, Nencki Institute of Experimental Biology, Polish Academy of Sciences, Warszawa, Poland. 3. Department of Histology, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland.
Abstract
BACKGROUND: Neuropeptides play an important role in various neural pathways, being able to control a wide spectrum of physiological responses. Neuropeptide Y (NPY) and proopiomelanocortin (POMC) functions are quite well studied, however little is known about their action at the level of limbic structures. The present work was focused on the expression of the aforementioned peptides in this brain structure of rats treated with olanzapine, a second generation neuroleptic drug. The detailed purpose of this experiment was the evaluation of potential relationships between chronic olanzapine administration and NPY and POMC mRNA expression in the amygdala and hippocampal formation. METHODS: The studies were carried out on adult, male Sprague-Dawley rats that were divided into 2 groups: control and experimental animals treated with olanzapine (28 day-long intraperitoneal injection). All individuals were sacrificed under anaesthesia, then the amygdaloid complexes and hippocampi were excised. Total mRNA was isolated from homogenized samples of both structures and the RT-PCR method was used for estimation of NPY and POMC gene relative expression. RESULTS: Prolonged olanzapine administration is reflected in qualitatively different changes in expression of NPY and POMC mRNA in the rat amygdala and hippocampus. Interestingly enough, olanzapine did not affect NPY expression, but significantly increased the POMC level in both examined regions. CONCLUSIONS: Olanzapine can affect amygdalar and hippocampal neuronal populations by the modulation of neuropeptide activity. Importantly, it may suggest the existence of an alternative mode of its action. Undoubtedly this hypothetic regulatory mechanism requires further pharmacological and neurostructural study.
BACKGROUND: Neuropeptides play an important role in various neural pathways, being able to control a wide spectrum of physiological responses. Neuropeptide Y (NPY) and proopiomelanocortin (POMC) functions are quite well studied, however little is known about their action at the level of limbic structures. The present work was focused on the expression of the aforementioned peptides in this brain structure of rats treated with olanzapine, a second generation neuroleptic drug. The detailed purpose of this experiment was the evaluation of potential relationships between chronic olanzapine administration and NPY and POMC mRNA expression in the amygdala and hippocampal formation. METHODS: The studies were carried out on adult, male Sprague-Dawley rats that were divided into 2 groups: control and experimental animals treated with olanzapine (28 day-long intraperitoneal injection). All individuals were sacrificed under anaesthesia, then the amygdaloid complexes and hippocampi were excised. Total mRNA was isolated from homogenized samples of both structures and the RT-PCR method was used for estimation of NPY and POMC gene relative expression. RESULTS: Prolonged olanzapine administration is reflected in qualitatively different changes in expression of NPY and POMC mRNA in the rat amygdala and hippocampus. Interestingly enough, olanzapine did not affect NPY expression, but significantly increased the POMC level in both examined regions. CONCLUSIONS:Olanzapine can affect amygdalar and hippocampal neuronal populations by the modulation of neuropeptide activity. Importantly, it may suggest the existence of an alternative mode of its action. Undoubtedly this hypothetic regulatory mechanism requires further pharmacological and neurostructural study.
Authors: Aneta Piwowarczyk-Nowak; Artur Pałasz; Aleksandra Suszka-Świtek; Alessandra Della Vecchia; Aniela Grajoszek; Marek Krzystanek; John J Worthington Journal: Pharmacol Rep Date: 2022-06-02 Impact factor: 3.919
Authors: Christina N Vallianatos; Brynne Raines; Robert S Porter; Katherine M Bonefas; Michael C Wu; Patricia M Garay; Katie M Collette; Young Ah Seo; Yali Dou; Catherine E Keegan; Natalie C Tronson; Shigeki Iwase Journal: Commun Biol Date: 2020-06-01
Authors: Artur Pałasz; Aneta Piwowarczyk-Nowak; Aleksandra Suszka-Świtek; Katarzyna Bogus; Łukasz Filipczyk; Alessandra Della Vecchia; Kinga Mordecka-Chamera; Itiana Castro Menezes; John J Worthington; Marek Krzystanek; Ryszard Wiaderkiewicz Journal: Mol Biol Rep Date: 2020-09-10 Impact factor: 2.316